MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval

Thanyanan ReungwetwattanaSai Hong Ignatius OuMahidol UniversityUCI School of Medicine2018-11-232018-11-232015-01-01Translational Lung Cancer Research. Vol.4, No.6 (2015), 820-82422264477221867512-s2.0-84960130558https://repository.li.mahidol.ac.th/handle/123456789/36805Mahidol UniversityMedicineMET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalNoteSCOPUS10.3978/j.issn.2218-6751.2015.12.03